Updated:
Athos KG (Strüngmann Family Office)
Athos KG was founded in 2006 by the Strüngmann brothers following the 2005 sale of Hexal AG. Their wealth originated in the German generics and pharmaceutical...
Athos KG (Strüngmann Family Office)
Athos KG was founded in 2006 by the Strüngmann brothers following the 2005 sale of Hexal AG. Their wealth originated in the German generics and pharmaceutical sector. The office maintains its headquarters in Holzkirchen near Munich. Athos KG allocates across private equity, venture growth, real estate and public markets. Confirmed positions include BioNTech, WS Audiology, AMSilk GmbH, Formycon AG and AAVantgarde Bio. The firm participates in both direct co-investments and fund commitments alongside partners such as EQT AB, MIG Capital and Redmile Group. Activity spans Germany, the United Kingdom and other European markets. Investment stages range from seed through buyout. The office employs a compact internal team led by named executives including Helmut Jeggle. Adjacent holdings include mixed-use properties such as Fünf Höfe in Munich and Villa Kennedy in Frankfurt. No recent operational events from the last 24 months appear in available records. Athos KG maintains a distinct governance structure through its integration with the Ernst Strüngmann Foundation and the Ernst Strüngmann Institute for Neuroscience. This arrangement links investment decisions to long-term scientific and philanthropic commitments rather than external LP mandates.
General information
Firm type
Single Family Office
Year founded
2006
Location
Region
Europe
Country
Germany
City
Holzkirchen
Corporate office
Bergfeldstrasse 9, 83607 Holzkirchen, Germany
Principals
Andreas Strüngmann
Founder
Thomas Strüngmann
Founder
Helmut Jeggle
Former Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Athos KG?
Andreas Strüngmann and Thomas Strüngmann set overall direction. Helmut Jeggle previously served as managing partner and continues on portfolio boards including BioNTech.
Does Athos KG participate in fund commitments or only direct deals?
Athos KG executes both direct co-investments and commitments to external funds. Examples include co-investments in BioNTech alongside Redmile Group and MIG Capital.
What investment stages does Athos KG typically target?
The office covers seed through buyout stages. Portfolio examples range from early-stage AAVantgarde Bio to growth and buyout positions in healthcare services.
Where does the underlying wealth come from?
Wealth originated from the Strüngmann brothers' founding and sale of Hexal AG, a German generics pharmaceutical company acquired by Novartis in 2005.
How is Athos KG related to the Ernst Strüngmann Institute?
The Ernst Strüngmann Foundation financed the institute, which maintains close cooperation with the Max Planck Society. This structure connects family capital to neuroscience research.
Which sectors does Athos KG explicitly avoid?
No explicit avoidance list is disclosed. Activity concentrates on healthcare, climate technology, industrial tech and real estate.
Does Athos KG maintain philanthropic structures, and how are they separated?
The family operates the Andreas and Susan Struengmann Foundation and the Ernst Strüngmann Foundation. These vehicles sit alongside but separate from the investment activities of Athos KG.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: